Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 9 · below the Ichimoku cloud · RSI 29 (oversold) · MACD below its signal
| 16.93 | 52-week high | +70.29% |
| 12.98 | Previous month high | +30.58% |
| 12.84 | Previous week high | +29.12% |
| 10.82 | Previous month low | +8.85% |
| 10.68 | Previous week low | +7.44% |
| 10.63 | R3 (classic) | +6.96% |
| 10.49 | R2 (classic) | +5.54% |
| 10.35 | Previous day high | +4.12% |
| 10.22 | R1 (classic) | +2.77% |
| 10.07 | Pivot | +1.35% |
| 9.94 | Price now | |
| 9.93 | Previous day low | −0.06% |
| 9.80 | S1 (classic) | −1.42% |
| 9.66 | S2 (classic) | −2.83% |
| 9.38 | S3 (classic) | −5.61% |
| 8.48 | 52-week low | −14.69% |
None of the 29 investors followed here reported a position in INKT in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a INKT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 11, 2026 | Buell JenniferChief Executive Officer | Sale at price 10.56 per share. | 6.9K | $73.27K |
| Oct 8, 2026 | Buell JenniferChief Executive Officer | — | 23.2K | — |
| Aug 31, 2026 | Ryan BarbaraDirector | Stock Award(Grant) at price 10.95 per share. | 1.6K | $17.76K |
| Aug 31, 2026 | Behner PeterDirector | Stock Award(Grant) at price 10.95 per share. | 1.5K | $16.26K |
| Aug 31, 2026 | Holcomb John Bradley M.D.Director | Stock Award(Grant) at price 10.95 per share. | 1.2K | $13.50K |
| Aug 31, 2026 | Wiinberg UlfDirector | Stock Award(Grant) at price 10.95 per share. | 1.3K | $14.01K |
| Aug 31, 2026 | Corvese Brian JDirector | Stock Award(Grant) at price 10.95 per share. | 1.6K | $17.88K |
| Jun 3, 2026 | Ryan BarbaraDirector | Sale at price 12.68 - 12.80 per share. | 1.5K | $19.14K |
| May 31, 2026 | Ryan BarbaraDirector | Stock Award(Grant) at price 10.90 - 12.38 per share. | 3.1K | $35.51K |
| May 31, 2026 | Behner PeterDirector | Stock Award(Grant) at price 10.90 - 12.38 per share. | 2.8K | $32.51K |
| May 31, 2026 | Holcomb John Bradley M.D.Director | Stock Award(Grant) at price 10.90 - 12.38 per share. | 2.3K | $27.01K |
| May 31, 2026 | Wiinberg UlfDirector | Stock Award(Grant) at price 10.90 - 12.38 per share. | 2.4K | $28.01K |
| May 31, 2026 | Corvese Brian JDirector | Stock Award(Grant) at price 10.90 - 12.38 per share. | 3.1K | $35.75K |
| Mar 9, 2026 | Ryan BarbaraDirector | Sale at price 10.17 - 15.57 per share. | 1.5K | $22.05K |
| Mar 1, 2026 | Ryan BarbaraDirector | Sale at price 10.83 - 10.86 per share. | 500 | $5.43K |
| Jan 1, 2026 | Buell JenniferChief Executive Officer | Stock Award(Grant) at price 11.12 per share. | 31.5K | $349.99K |
| Jan 1, 2026 | Buell JenniferChief Executive Officer | Stock Award(Grant) at price 11.12 per share. | 31.5K | $349.99K |
| Nov 30, 2025 | Ryan BarbaraDirector | Stock Award(Grant) at price 11.09 per share. | 1.6K | $17.75K |
| Nov 30, 2025 | Behner PeterDirector | Stock Award(Grant) at price 11.09 per share. | 1.5K | $16.26K |
| Nov 30, 2025 | Kadlec Robert PeterDirector | Stock Award(Grant) at price 11.09 per share. | 1.2K | $13.51K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.7 | -7.0 | -3.8 | 15.9 | 0.0 | -4.2 | -10.2 | 5.6 | 13.2 | -20.8 | −10.9% | ||
| 2025 | 31.4 | -2.3 | -3.5 | -13.8 | -5.7 | 5.1 | 105.2 | -6.1 | -1.7 | 0.3 | -25.1 | 6.1 | +60.0% |
| 2024 | -19.2 | 6.5 | -1.4 | 9.0 | -2.0 | -2.2 | -0.9 | -13.8 | -7.4 | -4.8 | 2.7 | -4.9 | −34.9% |
| 2023 | -12.4 | -11.2 | -6.7 | -5.5 | -1.7 | 19.3 | -11.0 | -22.5 | -24.1 | -7.3 | 2.9 | 1.9 | −59.0% |
| 2022 | -26.2 | -9.7 | -24.2 | -0.4 | -30.8 | -9.0 | -7.1 | 100.8 | -19.8 | 3.3 | 21.6 | -1.5 | −41.5% |
| 2021 | -35.2 | -61.6 | −75.1% |
Buy / hold / sell counts
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.